Who is sponsoring NCT00035256?

NCT00035256 is sponsored by Eli Lilly and Company.

What condition does NCT00035256 study?

NCT00035256 studies Osteoporosis, Postmenopausal.

What drugs are being tested in NCT00035256?

Interventions: teriparatide, raloxifene HCl, placebo.

What is the status of NCT00035256?

NCT00035256 is currently COMPLETED.

Last reviewed 2007-05-11 · How we verify

Sequential Use of Teriparatide and Raloxifene HCl in the Treatment of Postmenopausal Women With Osteoporosis

NCT00035256 Phase 4 COMPLETED

The purpose of this study is to determine whether the increase in spine bone mineral density that has been generally observed in previous clinical studies involving the study drug can be maintained or even increased if followed with raloxifene HCl. All qualifying study participants will receive the study drug followed by treatment with raloxifene HCl or placebo. All study participants will receive raloxifene HCl in the third phase of the study.

Details

Lead sponsor	Eli Lilly and Company
Phase	Phase 4
Status	COMPLETED
Enrolment	330
Start date	2001-10
Completion	2005-07

Conditions

Osteoporosis, Postmenopausal

Interventions

teriparatide
raloxifene HCl
placebo

Primary outcomes

The study is designed to compare the effect of 1 year of raloxifene treatment with the effect of placebo on maintaining teriparatide-induced increases in spine and hip BMD.

Countries

United States, Canada